Article
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
BMC medicine - 21 Mar 2012
Chen Gang, Kronenberger Peter, Teugels Erik, Umelo Ijeoma Adaku, De Grève Jacques
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung cancer (NSCLC). However, current single agent receptor targeting does not achieve a maximal therapeutic effect, and some mutations confer resistance to current available agents. In the current study we have examined, in different NSCLC cell lines, the combined effect of RNA interference targeting the...
Topics
- Afatinib
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Caspase 3
- Caspase 7
- Cell Line, Tumor
- Cell Proliferation
- Cetuximab
- Down-Regulation
- ErbB Receptors
- Erlotinib Hydrochloride